Fo­cused on da­ta and drug de­vel­op­ment, Soft­Bank hunts new $1B biotech deals — re­port

Soft­Bank’s mam­moth $1.1 bil­lion in­vest­ment in Vivek Ra­maswamy’s Roivant Sci­ences won’t like­ly be its last in biotech.

Quot­ing sources fa­mil­iar with the deal, Bloomberg is re­port­ing that the Japan­ese group’s glob­al $100 bil­lion eq­ui­ty fund has be­gun a re­cruit­ment cam­paign for sci­en­tists with an eye to back­ing more com­pa­nies that use new da­ta tech­nol­o­gy to iden­ti­fy drugs with sol­id de­vel­op­ment po­ten­tial.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.